Arcus Biosciences stock falls 2.79 percent before ARC-20 data

Published on 10/06/2026 at 16:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Arcus Biosciences stock was at USD 24.05 on October 6, 2026, with a USD 38.60 consensus target. The October 20 event will show ARC-20 data.

RCUS, US03969F1093, Illustration mit AI erstellt.

Arcus Biosciences (ISIN US03969F1093) was trading at USD 24.05 on the NYSE at 10:37 a.m. ET on October 6, 2026, down 2.79 percent from the prior close. The company is preparing an October 20 investor event for new ARC-20 data on casdatifan, its investigational kidney cancer therapy, according to Business Wire on September 22, 2026.

ARC-20 data arrives October 20

The New York event will cover casdatifan in first-line, second-line and late-line clear cell renal cell carcinoma. The agenda includes data from 30 patients in a first-line combination with zimberelimab, 43 patients in a second-line casdatifan and cabozantinib cohort, and 121 pooled late-line monotherapy patients, according to Business Wire.

Arcus expects the PEAK-1 Phase 3 study to complete enrollment and the PEAK-20 Phase 3 study to begin by the end of 2026. The company also cautions that casdatifan remains investigational, so the October readout is a clinical milestone rather than an approval event.

Quarterly revenue beat expectations

Arcus reported USD 41.0 million of revenue and a USD 0.72 quarterly EPS loss for the second quarter of 2026. Revenue was down 74.4 percent from the year-earlier quarter, but the EPS loss was USD 0.17 narrower than the USD 0.89 consensus loss, according to MarketBeat in its October 3, 2026 report.

The numbers show the central tension in the story: Arcus is still reporting large losses while the investment case depends on clinical progress. The October data must therefore support both the biological promise of casdatifan and the company's ability to advance PEAK-1 and PEAK-20.

Analysts see upside beyond the event

Analyst sentiment remains constructive. Markets Insider reported on October 5, 2026 that the consensus rating was Moderate Buy with a USD 38.60 price target, implying a 51.5 percent upside from the reference price used in that report.

Wedbush maintained an Outperform rating and a USD 43 price target on October 1, 2026, as reported by RTTNews. That target is tied directly to the expected casdatifan data, making October 20 the next measurable test for the bullish thesis.

Arcus stock trades below its yearly high

At USD 24.05 on the NYSE on October 6, 2026, Arcus had a market capitalization of USD 3.0 billion and a 52-week range of USD 13.71 to USD 31.74. The session volume was 141,749 shares, while the stock's current level remains below its yearly high as investors await clinical evidence.